American College of Cardiology

Use of prehospital ECGs reduces time to reperfusion, findings show

By Courtneay Parsons

Prehospital electrocardiograms reduce reperfusion times in patients with suspected ST-elevation myocardial infarction (STEMI) who are first evaluated by emergency medical services (EMS) personnel ...[more]

Experts discuss ENHANCE trial data, implications for clinical practice

By Courtneay Parsons

The addition of ezetimibe to simvastatin significantly reduces LDL cholesterol levels relative to simvastatin alone, but the combination does not offer additional benefit with respect to slowing the progression of atherosclerosis, 24-month ENHANCE ...[more]

Door-to-needle, door-to-balloon times have decreased since 1990s

By Nancy Stanley

Among patients with ST-segment elevation myocardial infarction (STEMI), in-hospital mortality has declined since the 1990s as a result of decreases in door-to-needle (DN) and door-to-balloon (DB) times, new data reveal.

To determine the trends ...[more]

Celecoxib increases cardiovascular risk in dose-, regimen-related fashion

By Nancy Stanley

Patients who receive celecoxib have an increased cardiovascular risk relative to patients who receive placebo, and the risk may vary based on the dose and dose regimen of celecoxib, new data ...[more]

Pioglitazone prevents progression of coronary atherosclerosis in patients with CAD, diabetes

By Nancy Stanley

Treatment with pioglitazone appears to result in a significantly lower rate of progression of coronary atherosclerosis relative to treatment with glimepiride in patients with coronary artery disease and type 2 diabetes, results of a new study show.
...[more]

Data suggest AT/AF burden stratifies risk of thromboembolic events

By Courtneay Parsons

Device-detected atrial tachycardia/atrial fibrillation (AT/AF) burden may be useful for stratifying the risk for thromboembolic events (TE), according to data from the TRENDS study.

Dr. ...[more]

Telmisartan as effective as ramipril, better tolerated

By Nancy Stanley

New data from the ONTARGET trial show that telmisartan is as effective as ramipril at reducing cardiovascular risk while resulting in fewer side effects. However, the combination of telmisartan and ramipril does not ...[more]

Rosuvastatin yields regression in coronary atherosclerosis

By Nancy Stanley

Rosuvastatin lowers LDL cholesterol, increases HDL cholesterol, and produces regression by decreasing percent diameter stenosis and improving minimum lumen diameter (MLD) as measured by quantitative coronary angiography in statin-naive patients with coronary ...[more]

Amlodipine/benazepril reduces adverse cardiovascular outcomes, death in patients with hypertension

By Nancy Stanley

A fixed-dose, single-pill combination of a calcium channel blocker and an ACE inhibitor, amlodipine besylate/benazepril hydrochloride, appears to significantly reduce cardiovascular morbidity and mortality relative ...[more]

STRADIVARIUS trial fails to show effect of rimonabant in primary IVUS endpoint, but secondary endpoint data suggest drug might reduce atherosclerosis progression

By Courtneay Parsons

Results of the STRADIVARIUS trial failed to show a significant effect of the cannabinoid receptor (CB1) antagonist rimonabant on the percent change in atheroma volume, the study's primary endpoint. ...[more]

CARISMA researchers use ILR to document arrhythmias in post-MI patients with low ejection fraction, identify high-degree AV block as independent predictor of cardiac death

By Courtneay Parsons

Results from the CARISMA study suggest new-onset atrial fibrillation and potentially serious bradyarrhythmias and ventricular tachyarrhythmias occur in a substantial number of patients who have an ejection fraction <=0.40 following an acute ...[more]

Cardiac resynchronization therapy might benefit asymptomatic, mildly symptomatic patients with HF, according to 12-month REVERSE trial data

By Courtneay Parsons

Although cardiac resynchronization therapy (CRT) did not demonstrate a statistically significant benefit in the REVERSE trial's primary endpoint, other data from the trial suggest CRT reverses left ...[more]